POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.12.2021, 3:33pm CEST, WHO):   U.S. 13,304    India 84,332    Brazil 88,092    France 3,639    Turkey 6,261    Russia 13,510    The United Kingdom 7,958    Italy 1,892    Argentina 27,628    Germany 1,911    Columbia 29,302    Iran 9,966    Mexico 3,672    Ukraine 1,274    Peru 4,054    Indonesia 8,083    South Africa 8,020    The Netherlands 1,417    Chile 7,941    Canada 1,476    Philippines 6,686    Iraq 4,320    Pakistan 1,303    Bangladesh 2,454    Japan 1,920    Malaysia 6,849    Nepal 2,709    United Arab Emirates 2,281    Saudi Arabia 1,175    Ecuador 1,098    Belarus 1,026    Bolivia 3,233    Paraguay 2,758    Tunisia 2,161    Costa Rica 2,041    Uruguay 3,622    Kuwait 1,657    Dominican Republic 1,129    Guatemala 1,861    Venezuela 1,083    Sri Lanka 2,789    Thailand 3,277    Cuba 1,288    Zambia 2,065    Afghanistan 1,024    Mongolia 1,622    Namibia 1,432    Botswana 1,392    Uganda 1,566    China 322    Singapore 9    New Zealand 0    Australia 3    South Korea 565   

Existing anti-parasitic drug could offer treatment for Ebola

Christian Fernsby |
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly, highly contagious infection.

Article continues below




In meticulous experiments in human cells, led by Boston Children's Hospital, the drug significantly amplified immune responses to Ebola and inhibited Ebola replication.

The study, published in the Cell Press journal iScience, also showed how the drug works: It enhances the immune system's ability to detect Ebola, normally impeded by the virus.

Nitazoxanide, or NTZ, is currently used to treat gastrointestinal infections caused by parasites such as Giardia and Cryptosporidium.

It has been shown to be safe and even comes in a formulation for children.

Study leader Anne Goldfeld, MD, of the Program in Cellular and Molecular Medicine at Boston Children's, hopes that, with further testing and validation, it could be part of the solution for Ebola.

"Currently, there is no easily deployable therapy for Ebola virus," she says.

"There are some very promising vaccines, but there is no oral, inexpensive medication available."

The Ebola virus caused more than 10,000 deaths in the 2014-2016 West African epidemic and more than 1,800 lives (as of August 6th) in the current outbreak in the Democratic Republic of the Congo.

The virus is very good at evading human immune defenses.

Though very small, it has two genes devoted to blocking immune responses.

Goldfeld and collaborators Chad Mire, Ph.D. and Thomas Geisbert, Ph.D. from the University of Texas Medical Branch, Galveston, showed in Biosafety Level 4 laboratory experiments that NTZ inhibits the Ebola virus (isolated from an earlier outbreak).

Additional experiments performed in collaboration with Sun Hur, Ph.D. f Boston Children's showed that NTZ works by broadly amplifying the interferon pathway and cellular viral sensors, including two known as RIG-I and PKR.

By deleting RIG-I and PKR in human cells through CRISPR editing, Goldfeld and University of Texas colleagues showed that NTZ works through these molecules to inhibit Ebola virus.

"Ebola masks RIG-I and PKR, so that cells don't perceive that Ebola is inside," explains Goldfeld.

"This lets Ebola get a foothold in the cell and race ahead of the immune response.

"What we've been able to do is enhance the host viral detection response with NTZ.

It's a new path in treating Ebola."

Goldfeld hopes to move into animal studies soon, especially given that NTZ has already been used in millions of people with minimal side effects.

If effective, it could thus be easily repurposed for Ebola treatment or prevention.


What to read next

Ebola, very infectious but not very contagious disease
Ebola virus infects reproductive organs in monkeys, humans may be hit too
Experimental Ebola vaccines elicit year-long immune response